Wilma A Stolk Selected Research

Ivermectin (Mectizan)

1/2021	What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
1/2021	How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
1/2021	Scaling-Down Mass Ivermectin Treatment for Onchocerciasis Elimination: Modeling the Impact of the Geographical Unit for Decision Making.
1/2021	Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.
1/2021	The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.
10/2020	A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa-coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon.
1/2020	Projected Number of People With Onchocerciasis-Loiasis Coinfection in Africa, 1995 to 2025.
1/2019	Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities.
1/2018	Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
1/2018	How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wilma A Stolk Research Topics

Disease

25	Onchocerciasis 01/2021 - 01/2013
15	Filarial Elephantiasis (Lymphatic Filariasis) 01/2021 - 11/2003
8	Infections 01/2020 - 01/2005
4	Neglected Diseases 01/2021 - 01/2017
4	Ocular Onchocerciasis (River Blindness) 01/2021 - 04/2015
3	Trachoma 01/2021 - 02/2016
3	Schistosomiasis (Bilharziasis) 01/2021 - 02/2016
2	COVID-19 01/2021 - 01/2021
2	Helminthiasis (Helminthiases) 01/2021 - 01/2015
1	Skin Manifestations 01/2021
1	Loiasis 01/2020
1	Coinfection 01/2020
1	Chagas Disease (American Trypanosomiasis) 02/2016
1	Visceral Leishmaniasis (Kala Azar) 02/2016
1	Leprosy (Hansen's Disease) 02/2016
1	African Trypanosomiasis (Nagana) 02/2016
1	Strongyloidiasis 01/2015
1	Parasitic Diseases (Parasitic Disease) 01/2015
1	Trichuriasis 01/2015
1	Communicable Diseases (Infectious Diseases) 01/2015
1	Ascariasis 01/2015
1	Scabies (Sarcoptic Mange) 01/2015
1	Neoplasms (Cancer) 12/2012
1	Malaria 07/2008

Drug/Important Bio-Agent (IBA)

24	Ivermectin (Mectizan)FDA Link 01/2021 - 11/2005
6	Apolipoproteins C (ApoC)IBA 01/2021 - 01/2013
3	Albendazole (Albenza)FDA Link 01/2019 - 05/2006
3	Pharmaceutical PreparationsIBA 10/2018 - 11/2003
3	Diethylcarbamazine (Hetrazan)FDA Link 01/2018 - 11/2005
2	Indicators and Reagents (Reagents)IBA 10/2018 - 01/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	AS 8IBA 10/2018
1	Immunoglobulin G (IgG)IBA 01/2017
1	Antiparasitic Agents (Antiparasitics)IBA 01/2016
1	pyrimethamine drug combination fanasil (Fansidar)FDA Link 07/2008

Therapy/Procedure

21	Mass Drug Administration 01/2021 - 01/2005
3	Drug Therapy (Chemotherapy) 01/2021 - 02/2016
2	Ambulatory Care (Outpatient Care) 01/2017 - 12/2012
1	Aftercare (After-Treatment) 10/2020
1	Insecticide-Treated Bednets 07/2008
1	Therapeutics 05/2006